These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 18618371)

  • 1. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Scand J Gastroenterol; 2008; 43(10):1202-11. PubMed ID: 18618371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
    Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
    Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R; Ameen V; Gordon SH; West M; Heath AT; Perschy T; Carter EG
    Am J Gastroenterol; 2007 Aug; 102(8):1709-19. PubMed ID: 17509028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
    Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
    Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of dioctahedral smectite in treating patients of diarrhea-predominant irritable bowel syndrome.
    Chang FY; Lu CL; Chen CY; Luo JC
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2266-72. PubMed ID: 17559369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q; Zhang Y; Chen F; Zuo X; Li Y
    BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R; Nikfar S; Abdollahi M
    Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.
    Chey WD; Chey WY; Heath AT; Dukes GE; Carter EG; Northcutt A; Ameen VZ
    Am J Gastroenterol; 2004 Nov; 99(11):2195-203. PubMed ID: 15555002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Hayashi K; Akiho H; Nakashima Y; Haruma K
    J Gastroenterol; 2016 Sep; 51(9):874-82. PubMed ID: 26800997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.
    Tack JF; Miner PB; Fischer L; Harris MS
    Aliment Pharmacol Ther; 2011 Oct; 34(8):868-77. PubMed ID: 21883322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L; Ameen VZ; Dukes GE; McSorley DJ; Carter EG; Mayer EA
    Am J Gastroenterol; 2005 Jan; 100(1):115-23. PubMed ID: 15654790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.
    Dove LS; Lembo A; Randall CW; Fogel R; Andrae D; Davenport JM; McIntyre G; Almenoff JS; Covington PS
    Gastroenterology; 2013 Aug; 145(2):329-38.e1. PubMed ID: 23583433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peppermint oil (Mintoil) in the treatment of irritable bowel syndrome: a prospective double blind placebo-controlled randomized trial.
    Cappello G; Spezzaferro M; Grossi L; Manzoli L; Marzio L
    Dig Liver Dis; 2007 Jun; 39(6):530-6. PubMed ID: 17420159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome].
    Tegaserod Clinical Research Group
    Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind, placebo-controlled trial of the 5-HT1A receptor antagonist AZD7371 tartrate monohydrate (robalzotan tartrate monohydrate) in patients with irritable bowel syndrome.
    Drossman DA; Danilewitz M; Naesdal J; Hwang C; Adler J; Silberg DG
    Am J Gastroenterol; 2008 Oct; 103(10):2562-9. PubMed ID: 18775020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.